Trial Profile
10-week, open, national, multicenter clinical trial to evaluate the safety of insulin glargine in type 2 diabetes mellitus patients, on intensified conventional therapy (ICT)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Sep 2006
Price :
$35
*
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Acronyms SAFIR
- Sponsors Sanofi
- 13 Sep 2006 New trial record.